Journal article
F-19-MRI for monitoring human NK cells in vivo
Oncoimmunology, Vol.5(5), e1143996
01/01/2016
DOI: 10.1080/2162402X.2016.1143996
PMCID: PMC4910731
PMID: 27467963
Abstract
The availability of clinical-grade cytokines and artificial antigen-presenting cells has accelerated interest in using natural killer (NK) cells as adoptive cellular therapy (ACT) for cancer. One of the technological shortcomings of translating therapies from animal models to clinical application is the inability to effectively and non-invasively track these cells after infusion in patients. We have optimized the nonradioactive isotope fluorine-19 (F-19) as a means to label and track NK cells in preclinical models using magnetic resonance imaging (MRI). Human NK cells were expanded with interleukin (IL)-2 and labeled in vitro with increasing concentrations of F-19. Doses as low as 2 mg/mL F-19 were detected by MRI. NK cell viability was only decreased at 8 mg/mL F-19. No effects on NK cell cytotoxicity against K562 leukemia cells were observed with 2, 4 or 8 mg/mL F-19. Higher doses of F-19, 4 mg/mL and 8 mg/mL, led to an improved F-19 signal by MRI with 3 x 10(11) F-19 atoms per NK cell. The 4 mg/mL F-19 labeling had no effect on NK cell function via secretion of granzyme B or interferon gamma (IFN gamma), compared to NK cells exposed to vehicle alone. F-19-labeled NK cells were detectable immediately by MRI after intratumoral injection in NSG mice and up to day 8. When F-19-labeled NK cells were injected subcutaneously, we observed a loss of signal through time at the site of injection suggesting NK cell migration to distant organs. The F-19 perfluorocarbon is a safe and effective reagent for monitoring the persistence and trafficking of NK cell infusions in vivo, and may have potential for developing novel imaging techniques to monitor ACT for cancer.
Details
- Title: Subtitle
- F-19-MRI for monitoring human NK cells in vivo
- Creators
- Myriam N. Bouchlaka - University of Wisconsin–MadisonKai D. Ludwig - University of Wisconsin–MadisonJeremy W. Gordon - University of Wisconsin–MadisonMatthew P. Kutz - University of Wisconsin–MadisonBryan P. Bednarz - University of Wisconsin–MadisonSean B. Fain - University of Wisconsin–MadisonChristian M. Capitini - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- Oncoimmunology, Vol.5(5), e1143996
- Publisher
- Taylor & Francis
- DOI
- 10.1080/2162402X.2016.1143996
- PMID
- 27467963
- PMCID
- PMC4910731
- ISSN
- 2162-402X
- eISSN
- 2162-402X
- Number of pages
- 12
- Grant note
- P30CA014520 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) UWCCC American Association of Immunologists Careers in Immunology Fellowship SU2C-AACR-DT1113 / Stand Up To Cancer - St. Baldrick's Pediatric Dream Team Translational Research Grant P30 CA014520 - UWCCC / NCI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) K08 CA174750 / NIH/NCI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) American Cancer Society Alex's Lemonade Stand Foundation UL1TR000427; TL1TR000429 / NIH/NCATS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) St. Baldrick's Foundation
- Language
- English
- Date published
- 01/01/2016
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiology; Electrical and Computer Engineering; Health and Human Physiology
- Record Identifier
- 9984275054102771
Metrics
2 Record Views